Related Experiment Video

Updated: Sep 12, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Harnessing tyrosine kinase 2: Breakthroughs in autoimmune disease and cancer therapy

Fei-Long Li1, Xin-Jie Wu1, Hong-Yan Feng1

  • 1Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, PR China.

Bioorganic Chemistry
|August 9, 2025
PubMed

Insights

Selective TYK2 inhibitors offer a promising therapeutic strategy for autoimmune diseases and cancer by minimizing side effects associated with traditional JAK inhibitors. This review details TYK2

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Tyrosine Kinase 2 (TYK2) is vital for cytokine signaling within the Janus Kinase (JAK) family.
  • Non-selective JAK inhibitors present risks of adverse effects and diminished efficacy.
  • Targeting TYK2 selectively offers a therapeutic advantage by reducing off-target impacts.

Purpose of the Study:

  • To review the structure, biological functions, and signaling pathways of TYK2.
  • To explore the therapeutic potential of TYK2 inhibitors in autoimmune diseases and cancer.
  • To summarize the advancements in TYK2 inhibitor development, including single-target, dual-target, and degraders.

Main Methods:

  • Literature review of TYK2 structure, JAK/STAT pathway, and inhibitor development.
  • Analysis of current research on TYK2 small molecule inhibitors.
  • Discussion of challenges and future strategies in TYK2 research.

Main Results:

  • TYK2 inhibitors represent a targeted approach to modulate immune responses.
  • Various TYK2 inhibitor modalities are under investigation, including degraders.
  • Understanding TYK2's role is crucial for developing effective treatments.

Conclusions:

  • Selective TYK2 inhibition is a promising strategy for treating autoimmune conditions and cancers.
  • Further research is needed to overcome challenges in TYK2 inhibitor development.
  • TYK2 inhibitors hold potential for improved therapeutic outcomes with reduced toxicity.
Keywords:
Autoimmune diseasesSignal transduction pathwaysTYK2 inhibitorsTYK2 kinase

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K